Finally, the authors also utilized this glycosylation signature to develop an antibody drug conjugate specifically binding to polyLacNAc containing PD-L1 that was validated in a syngeneic mouse model of human breast cancer 66. This evidence concerns the gene CD274 and breast cancer.